Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Rd, Tarrytown, NY 10591, USA.
Genesis Research, LLC, 111 River Street, Suite 1120, Hoboken, NJ 07030, USA.
Future Oncol. 2022 Dec;18(39):4385-4397. doi: 10.2217/fon-2022-0540. Epub 2023 Jan 19.
Trends/outcomes associated with National Comprehensive Cancer Network (NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer (aNSCLC) treatment were assessed. Patients initiating first-line aNSCLC treatment were included using a nationwide electronic health record-derived database (1/1/2015-10/31/2021). Trends in pre-first-line biomarker testing (PD-L1, major genomic aberrations), factors associated with testing and associations between testing and outcomes were assessed. PD-L1/genomic aberration testing rates increased from 33% (2016) to 81% (2018), then plateaued. Certain clinical and demographic factors were associated with a greater likelihood of PD-L1 testing. Patients tested for PD-L1 or genomic aberrations had longer overall survival (OS). Biomarker testing may be associated with improved OS in aNSCLC, though not all patients had equal access to testing.
评估了与美国国家综合癌症网络（NCCN）推荐的生物标志物检测相关的趋势/结果，以指导晚期非小细胞肺癌（aNSCLC）的治疗。使用全国范围内的电子健康记录衍生数据库（2015 年 1 月 1 日至 2021 年 10 月 31 日）纳入开始一线 aNSCLC 治疗的患者。评估了一线前生物标志物检测（PD-L1、主要基因组异常）的趋势、与检测相关的因素以及检测与结果之间的关联。PD-L1/基因组异常检测率从 33%（2016 年）增加到 81%（2018 年），然后趋于平稳。某些临床和人口统计学因素与 PD-L1 检测的可能性更大相关。接受 PD-L1 或基因组异常检测的患者总生存期（OS）更长。生物标志物检测可能与 aNSCLC 的 OS 改善相关，但并非所有患者都能平等获得检测。
